Stock vs Stock Comparison

argenx SE vs Abbott Laboratories

ARGX wins the Tale of the Tape 6–2.

ARGX$813.14
ABT$86.99

🏆 Tale of the Tape

62
ARGXABT
31.1%Profitability (Net Margin)14.7%
37.1xValuation (P/E)24.0x
13.8%Efficiency (ROIC)10.1%
5/9Health (Piotroski F)5/9
23.7Safety (Altman Z)4.9
89.6%Growth (Rev YoY)5.7%
1.13Risk (Sharpe 1Y)-1.05
0.19xBalance Sheet (D/E)0.64x
1.23%FCF Yield4.21%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.101
252-Day Correlation
0.013
126-Day Correlation

Low correlation — excellent diversification pair.

Fundamentals

MetricARGXABT
Market Cap$52.2B$149.1B
P/E Ratio37.1x24.0x
Forward P/E22.7x14.1x
P/B176.61x2.86x
Dividend Yield2.94%
Beta-0.060.65

Quantitative Metrics

MetricARGXABT
DCF Fair Value$264.40$57.20
DCF Upside-67.3%-43.2%
Piotroski F5/95/9
Altman Z23.754.87
Beneish M-1.49-2.53
FCF Yield1.23%4.21%
Net Debt/EBITDA-2.6x0.1x
ROIC13.8%10.1%
WACC8.0%9.4%
ROIC – WACC5.8pp0.7pp
Gross Margin89.1%56.4%
Net Margin31.1%14.7%
Rev Growth YoY89.6%5.7%
Sharpe (1Y)1.13-1.05
Max Drawdown 3Y-38.2%
FCF Payout Ratio56%

ARGX Price

Loading chart...

ABT Price

Loading chart...

ETF Exposure

ARGX found in:

IBB3.32%
VGK0.31%
SPDW0.15%
VSGX0.15%
VEA0.15%
CWI0.12%
VEU0.12%
VXUS0.11%
VT0.04%

ABT found in:

IHI16.06%
IYH2.88%
XLV2.85%
VHT2.55%
DGRW1.71%
XHE1.36%
NOBL1.34%
SDY0.99%
MGV0.78%
VIG0.71%
VFMV0.69%
SCHV0.68%
VYM0.65%
VTV0.61%
IWD0.58%
QUS0.57%
SPYV0.53%
VONV0.48%
IVV0.37%
SPLG0.37%
ESGV0.36%
ITOT0.33%
SCHX0.33%
SCHB0.30%
VOO0.26%
VONE0.24%
SPY0.24%
URTH0.24%
VTI0.23%
SPTM0.22%
ACWI0.20%
RSP0.17%
VT0.14%
ONEO0.08%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

ARGX vs ABT: Head-to-Head Analysis

argenx SE (ARGX) and Abbott Laboratories (ABT) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, ARGX leads 6–2 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, ARGX generates a return on invested capital (ROIC) of 13.8% compared to ABT's 10.1%. This suggests ARGX is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between ARGX and ABT is 0.101, indicating low correlation, making them an effective diversification pair in a portfolio context.

ARGX appears in 9 ETFs tracked by SecuritiesDB, while ABT appears in 34 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, ARGX or ABT?

Our quantitative analysis compares ARGX and ABT across nine fundamental dimensions. ARGX wins the Tale of the Tape 6–2. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are ARGX and ABT correlated?

The 252-day correlation between ARGX and ABT is 0.101. They have low correlation, offering good diversification.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.